Inactive Instrument

Company BICYCL Nasdaq

Equities

US0887861088

Biotechnology & Medical Research

Business Summary

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist (TICA). The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.

Sales per Business

USD in Million2022Weight2023Weight Delta
Chemically Synthesized Medicines
100.0 %
14 100.0 % 27 100.0 % +86.52%

Sales per region

USD in Million2022Weight2023Weight Delta
United Kingdom
100.0 %
14 100.0 % 27 100.0 % +86.52%

Managers

Managers TitleAgeSince
Chief Executive Officer 56 15-08-31
Director of Finance/CFO 45 23-07-16
Chief Operating Officer 50 20-12-31
Chief Tech/Sci/R&D Officer 55 15-12-31
Chief Tech/Sci/R&D Officer 56 16-12-31
Investor Relations Contact - 21-03-31
Corporate Officer/Principal - -
Comptroller/Controller/Auditor - 18-03-31
General Counsel - 20-04-22
Corporate Officer/Principal 64 23-03-30

Members of the board

Members of the board TitleAgeSince
Chairman 63 19-03-17
Director/Board Member 61 21-03-16
Director/Board Member 73 19-10-30
Director/Board Member 68 19-07-23
Director/Board Member 67 19-07-17
Founder 73 08-12-31
Chief Executive Officer 56 15-08-31
Director/Board Member - Feb. 19

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 37,880,303 4,333,333 ( 11.44 %) 0 11.44 %

Shareholders

NameEquities%Valuation
Paradigm BioCapital Advisors LP
12.52 %
3,707,001 12.52 % 93 M £
Deep Track Capital LP
11.79 %
3,490,506 11.79 % 88 M £
Baker Bros. Advisors LP
6.927 %
2,050,180 6.927 % 51 M £
Jefferies LLC
6.581 %
1,948,000 6.581 % 49 M £
Baker Bros. Advisors LP
6.049 %
1,790,390 6.049 % 45 M £
Tybourne Capital Management (HK) Ltd.
5.576 %
1,650,320 5.576 % 41 M £
First Light Asset Management LLC
5.238 %
1,550,471 5.238 % 39 M £
Armistice Capital LLC
5.189 %
1,536,000 5.189 % 39 M £
Morgan Stanley Capital Services LLC
3.477 %
1,029,225 3.477 % 26 M £
1,004,535 3.394 % 25 M £
NameEquities%Valuation
Cambridge Innovation Capital Ltd
5.917 %
1,751,437 5.917 % 44 M £
GSK PLC
5.168 %
1,529,561 5.168 % 38 M £
Baker Bros. Advisors LP
2.789 %
825,418 2.789 % 21 M £
Kevin Lee
1.319 %
390,428 1.319 % 10 M £
180,677 0.6104 % 5 M £
95,839 0.3238 % 2 M £
73,196 0.2473 % 2 M £
70,593 0.2385 % 2 M £
48,716 0.1646 % 1 M £
39,000 0.1318 % 978 510 £

Company contact information

Bicycle Therapeutics Plc

Granta Park Great Abington Portway Building

CB21 6GS, Cambridge

+44 1223 261 503

http://bicycletherapeutics.com
address BICYCL